0001193125-26-098454
SEC filingALX Oncology Holdings Inc. reported a net loss of $101.7 million for fiscal year 2025, driven by total operating expenses of $104.0 million, primarily from research and development ($77.0 million) and general and administrative costs ($23.9 million). The company generated no revenue, resulting in a loss from operations of $104.0 million. Interest income of $4.0 million partially offset the operating loss. Cash used in operating activities was $84.1 million, while investing activities provided $82.6 million mainly from investment maturities. The company ended the year with $59.0 million in total assets, including $16.4 million in cash and cash equivalents and $28.4 million in short-term investments. Total liabilities were $33.1 million, with stockholders' equity of $26.0 million. The net loss per share was $2.00 for both basic and diluted calculations.
ALX Oncology Holdings Inc. reported a net loss of $101.7 million for fiscal year 2025, with no revenue generated during the period. The company's loss from operations was $104.0 million, driven by total operating expenses of $104.0 million. Research and development expenses accounted for $77.0 million (74% of operating expenses), while general and administrative costs were $23.9 million. An impairment charge of $3.2 million contributed to the operating loss. Interest income of $4.0 million partially offset the operating loss, resulting in a loss before income taxes of $101.7 million. The company reported no income tax provision. Net loss per share was $2.00 for both basic and diluted calculations, based on 53.7 million weighted-average shares outstanding.
No revenue was reported for fiscal year 2025. The company is a clinical-stage biotechnology company focused on developing therapies for cancer patients, and as such, has not yet generated product revenue from commercial sales. All financial results reflect the company's research and development activities and administrative operations without any offsetting revenue streams.
With no revenue generated, the company reported negative operating and net income margins. Operating expenses totaled $104.0 million, consisting primarily of research and development ($77.0 million) and general and administrative costs ($23.9 million). The impairment charge of $3.2 million represented approximately 3% of total operating expenses. The company's cost structure remains heavily weighted toward research and development activities, which accounted for 74% of total operating expenses.
Net cash used in operating activities was $84.1 million for fiscal year 2025. Investing activities provided $82.6 million in cash, primarily from $134.4 million in investment maturities offset by $51.6 million in investment purchases. Financing activities provided $0.4 million in cash, mainly from equity offerings. The company ended the year with total assets of $59.0 million, including $16.4 million in cash and cash equivalents, $28.4 million in short-term investments, and $3.5 million in long-term investments. Total liabilities were $33.1 million, consisting of $24.6 million in current liabilities and $8.5 million in non-current liabilities. Stockholders' equity was $26.0 million, with accumulated deficit of $722.8 million.
The filing does not provide specific forward-looking guidance or management projections for future periods. As a clinical-stage biotechnology company, ALX Oncology continues to focus on research and development activities for its pipeline candidates. The company's ability to continue operations depends on its capacity to raise additional capital through equity or debt financing, as evidenced by the $58.9 million in proceeds from equity offerings during fiscal year 2025. No specific strategic priorities or risk factors beyond standard clinical development risks are detailed in the provided financial data.